The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development (Cooperative Agreement, Clinical Trial Optional)
ID: 359015Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359015
Timeline
    Description

    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development," aimed at enhancing the understanding of complex metabolic diseases, particularly Type 2 Diabetes (T2D). This initiative seeks to renew the AMP CMD UM1 program for an additional five years, focusing on the aggregation and collation of genetic data related to T2D and its complications, thereby facilitating research and therapeutic advancements in the field. The program is critical for leveraging human genetics to uncover disease mechanisms and potential biomarkers, with an estimated total funding of $3 million and the expectation of one award. Interested applicants, including small businesses and various organizations, should contact Dr. Norann Zaghloul at Norann.zaghloul@nih.gov or call 301-435-6677 for further details, with proposals due by March 1, 2026, and awards anticipated by December 1, 2026.

    Point(s) of Contact
    Norann Zaghloul, PhD National Institute of Diabetes and Digestive and Kidney Diseases
    (301) 435-6677
    Norann.zaghloul@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Collaborative Awards to Support Microphysiological System Pilot Studies in Type 2 Diabetes Research
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Collaborative Awards to Support Microphysiological System Pilot Studies in Type 2 Diabetes Research." This initiative aims to solicit applications for research focused on microphysiological systems (MPSs) that model type 2 diabetes, encouraging collaborative investigations that combine expertise in bioengineering, diabetes biology, and human metabolism. The program is particularly significant as it seeks to advance understanding of metabolic tissue interactions and the heterogeneity of type 2 diabetes, supporting small pilot studies to generate preliminary data. The estimated total funding for this program is $1,000,000, with four awards expected, and interested applicants can reach out to Dr. Albert J. Hwa at albert.hwa@nih.gov or by phone at 301-451-1525 for further information. The application process is anticipated to open with a synopsis posted on April 1, 2026, and close on July 5, 2026, with awards expected to be made in January 2027.
    Single Source: Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity for the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Clinical Trial Data Processing, Analysis, and Coordination Center. This initiative aims to renew support for core program activities, including the management, direction, and coordination of data processing and analysis to bolster the AMP SCZ Clinical Trial Network. The program is crucial for advancing research on pharmacological interventions for psychosis and requires collaboration among experts in clinical research and bioinformatics. The estimated total funding for this opportunity is $12 million, with one award anticipated. Interested applicants can reach out to Dr. Suzanne Garcia at suzanne.garcia@nih.gov or call 202-345-1260 for further information. Key dates include an estimated synopsis post date of September 24, 2025, and a close date of October 24, 2025, with project activities expected to commence on July 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source for Continuation of the Environmental Determinants of Diabetes in The Young Study (TEDDY) Data Coordinating Center (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for a single source cooperative agreement to support the continuation of the Environmental Determinants of Diabetes in The Young (TEDDY) Data Coordinating Center (DCC). This funding aims to facilitate the ongoing analysis of samples from a second case-control cohort and to provide resources for the closeout of the TEDDY study, which is crucial for understanding the prevention and treatment of type 1 diabetes. The total estimated funding for this opportunity is $6 million, with one award anticipated, and interested applicants can reach out to Dr. Arthur Castle at castlea@niddk.nih.gov or by phone at 301-594-7719 for further information. The estimated synopsis post date is September 26, 2025, with a closing date of October 26, 2025, and the project is expected to commence on July 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for Diabetes Research Centers (P30 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for Diabetes Research Centers (P30 Clinical Trial Optional), aimed at enhancing research collaboration and innovation in diabetes and related metabolic disorders. This initiative seeks to establish a community of preclinical and clinical researchers, providing access to specialized resources and a Pilot and Feasibility Program to foster significant advancements beyond individual project capabilities. With an estimated total program funding of $18.2 million and an award ceiling of $1 million, the NIH anticipates making approximately seven awards, encouraging applications from a diverse range of eligible entities, including non-domestic institutions and community-based organizations. Interested parties should prepare for the application process, as the estimated synopsis post date is July 30, 2025, with applications expected to be solicited by March 11, 2026, and awards anticipated by December 30, 2026. For further inquiries, contact Dr. Christopher J. Lynch at lynchcj@nih.gov or call 301-325-4232.
    Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for collaborative research projects focused on type 1 diabetes, specifically utilizing biosamples and data from established clinical studies. The objective is to advance the understanding of the disease's etiology and pathogenesis, with funding available for studies that aim to explore disease mechanisms, delay onset, and improve prevention strategies. A total of $5.5 million is committed for up to four awards in Fiscal Years 2026 and 2027, with application deadlines beginning on May 26, 2025, and a final submission date of March 9, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium through a cooperative agreement. This initiative aims to advance research on cardiovascular disease in individuals with type 1 diabetes by soliciting applications for discovery and mechanistic studies, leveraging the resources of the existing CARE-T1D consortium formed in 2024. The program is particularly focused on hypothesis-driven research utilizing multi-omics and molecular approaches, encouraging collaboration among experts in related fields such as type 2 diabetes and atherosclerosis. The estimated total funding for this program is $4.5 million, with approximately eight awards expected to be made. Interested applicants can reach out to Dr. Chandima Nishadi De Abrew Rajapakse at Chandima.rajapakse@nih.gov or by phone at 240-429-5197. The application process is set to open with a synopsis posting on April 1, 2026, and will close on July 1, 2026, with awards anticipated by March 1, 2027.
    ancient DNA for Modern Genomics (aDMG) Data Generation and Resource Center
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing an upcoming funding opportunity for the establishment of an ancient DNA for Modern Genomics (aDMG) Data Generation and Resource Center. This initiative aims to create an ethical resource of ancient and historical human DNA data to enhance research on contemporary human traits and biology, with a focus on producing high-quality whole-genome sequence data from approved ancient DNA sources. The program is significant for advancing studies in population genomics and human evolution, encouraging collaborations among experts in DNA sequencing, computational genomics, and related fields. The estimated total program funding is $2,750,000, with one award expected, and interested applicants should prepare for the application process, which will open following the publication of the Notice of Funding Opportunity (NOFO) in December 2025, with a closing date in March 2026. For further inquiries, potential applicants can contact Jennifer Troyer at jennifer.troyer@nih.gov or by phone at 301-312-3276.
    ancient DNA for Modern Genomics (aDMG) Coordination Center
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to solicit applications for the establishment of an ancient DNA for Modern Genomics (aDMG) Coordination Center, aimed at creating an ethical resource of ancient and historical human DNA data to enhance research on contemporary human traits and biology. The initiative will involve collaboration with researchers and local communities to identify and oversee sources of ancient DNA, fostering interdisciplinary investigations that integrate DNA sequencing, computational genomics, and insights into human evolution. With an estimated total program funding of $1.5 million and a projected award date of October 30, 2026, interested small businesses are encouraged to prepare for application submission, with the synopsis expected to be published by December 1, 2025. For further inquiries, potential applicants can contact Jennifer Troyer at jennifer.troyer@nih.gov or by phone at 301-312-3276.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated, high-risk multi-center clinical trials through the Notice of Funding Opportunity (NOFO) PA-25-147. This cooperative agreement (U01) aims to support innovative studies that address critical health issues related to diabetes, digestive diseases, and kidney conditions, requiring proposals to be hypothesis-driven and operationally classified as high-risk. The program emphasizes the importance of diverse perspectives in research and mandates that planning activities be completed prior to application submission. Interested applicants should note that the application period opens on January 3, 2025, with a submission deadline of November 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.